PARTI OVERVIEW We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central ne...
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001628280-26-022029 | EDGAR | 95K words |
| 2025-03-17 | 2024-12-31 | 0001628280-25-013088 | EDGAR | — |
| 2024-03-13 | 2023-12-31 | 0001628280-24-010788 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001628280-23-004666 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001628280-22-003819 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001628280-21-003069 | EDGAR | — |
| 2020-02-28 | 2019-12-31 | 0001628280-20-002582 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001564590-19-005808 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001564590-18-004163 | EDGAR | — |
| 2017-02-28 | 2016-12-31 | 0001564590-17-002900 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001001233-25-000024 | EDGAR | 32K words |
| 2025-08-07 | 2025-06-30 | 0001628280-25-038860 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001628280-25-024650 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001628280-24-047102 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001628280-24-035165 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001628280-24-022194 | EDGAR | — |
| 2023-11-01 | 2023-09-30 | 0001628280-23-035989 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001628280-23-028200 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001628280-23-016486 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001628280-22-028168 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-021140 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001628280-22-012629 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001628280-26-022006 | EDGAR | 4K words |
| 2026-02-04 | 0001193125-26-036792 | EDGAR | — |
| 2026-02-03 | 0001001233-26-000005 | EDGAR | — |
| 2026-02-03 | 0001001233-26-000002 | EDGAR | — |
| 2025-11-06 | 0001001233-25-000023 | EDGAR | — |
| 2025-10-29 | 0001001233-25-000015 | EDGAR | — |
| 2025-09-30 | 0001001233-25-000013 | EDGAR | — |
| 2025-09-11 | 0001001233-25-000011 | EDGAR | — |
| 2025-09-04 | 0001001233-25-000006 | EDGAR | — |
| 2025-08-07 | 0001628280-25-038855 | EDGAR | — |
256 total filings indexed. 224 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001001233 |
| Ticker | SGMO |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.sangamo.com |
| Listed | 2000-04-06 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report